These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 16006264)
1. Time course of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients presenting with acute coronary syndrome. Bertsch T; Sueselbeck T; Wolpert C; Hoffmann U; Kaden JJ; Haase KK; Borggrefe M; Brueckmann M Clin Chem Lab Med; 2005; 43(6):660-3. PubMed ID: 16006264 [No Abstract] [Full Text] [Related]
2. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334 [TBL] [Abstract][Full Text] [Related]
3. Cell distribution differences of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in patients with Kawasaki disease. Korematsu S; Ohta Y; Tamai N; Takeguchi M; Goto C; Miyahara H; Kawano T; Izumi T Pediatr Infect Dis J; 2012 Sep; 31(9):973-4. PubMed ID: 22895216 [TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure. Gerlach RF; Tanus-Santos JE Am Heart J; 2006 Jul; 152(1):e9. PubMed ID: 16824824 [No Abstract] [Full Text] [Related]
5. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in multiple sclerosis. Gerlach RF; Tanus-Santos JE Clin Neurol Neurosurg; 2006 Sep; 108(6):617-8; author reply 618. PubMed ID: 16413675 [No Abstract] [Full Text] [Related]
6. Validating sampling methods for measurement of circulating matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1. Zhang RY; Cui W; Zhao KJ; Tang YQ; Li L Pancreas; 2010 Aug; 39(6):937; author reply 937-8. PubMed ID: 20664481 [No Abstract] [Full Text] [Related]
7. Seasonal variation and stability of matrix metalloproteinase-9 activity and tissue inhibitor of matrix metalloproteinase-1 with storage at -80°C. Tarr GP; Williams MJ; Phillips LV; van Rij AM; Jones GT Clin Biochem; 2011 Nov; 44(16):1346-8. PubMed ID: 21939646 [TBL] [Abstract][Full Text] [Related]
8. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease]. Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301 [TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in plasma/serum and urine of women during term and threatened preterm labor: a clinical approach. Makrakis E; Grigoriou O; Kouskouni E; Vitoratos N; Salamalekis E; Chatzoudi E; Creatsas G J Matern Fetal Neonatal Med; 2003 Sep; 14(3):170-6. PubMed ID: 14694972 [TBL] [Abstract][Full Text] [Related]
10. The Use of Serum MMP-9 and TIMP-1 in Acute Coronary Syndrome. Lahdentausta L; Sorsa T; Pesonen E; Pussinen P J Cardiovasc Transl Res; 2018 Dec; 11(6):526-527. PubMed ID: 30251220 [No Abstract] [Full Text] [Related]
11. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease]. Chen R; Zhang AR; Zhao XX; Li ZH Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606 [TBL] [Abstract][Full Text] [Related]
12. Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients. Dabek J; Glogowska-Ligus J; Szadorska B J Postgrad Med; 2013; 59(2):115-20. PubMed ID: 23793312 [TBL] [Abstract][Full Text] [Related]
13. Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Alby C; Ben Abdesselam O; Foglietti MJ; Beaudeux JL Clin Chim Acta; 2002 Nov; 325(1-2):183-6. PubMed ID: 12367785 [No Abstract] [Full Text] [Related]
14. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and tumour necrosis factor alpha release during cardiopulmonary bypass. Galley HF; Macaulay GD; Webster NR Anaesthesia; 2002 Jul; 57(7):659-62. PubMed ID: 12059824 [TBL] [Abstract][Full Text] [Related]
15. Effect of oral adsorbent AST-120 on plasma metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 concentrations in chronic renal failure. Ebihara I; Nakamura T; Ushiyama C; Suzuki S; Shimada N; Koide H Nephron; 1999; 83(2):169. PubMed ID: 10516499 [No Abstract] [Full Text] [Related]
16. Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2. Zhou SF; Hu SY; Ma L; Miao L; Mao WZ Chin Med J (Engl); 2013; 126(10):1925-9. PubMed ID: 23673111 [TBL] [Abstract][Full Text] [Related]
18. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Brunner S; Kim JO; Methe H Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234 [TBL] [Abstract][Full Text] [Related]